Mefloquine, a potent blood schizontocide, is effective against drug-resistant Plasmodium
falciparum. This property, along with its unique pharmacokinetic profile, makes mefloquine a …

Malaria puts more than 3 billion people at risk of infection and causes high morbidity and
mortality. Plasmodium vivax forms hypnozoites, which may initiate recurrences, even in the …

Due to the need of early and emergency effective treatments for COVID-19, less attention
may have been paid to their safety during the global emergency. In addition, characteristics …

Malaria is a deadly disease caused by a protozoan parasite whose mode of transmission is
through a female Anopheles mosquito. It affects persons of all ages; however, pregnant …

Abstract Context: The resistance of Plasmodium species to many available antimalarials
calls for a continuous search for newer antimalarial agents. One possible source of new …

Cerebral malaria (CM), a potentially fatal encephalopathy caused primarily by infection with
Plasmodium falciparum, results in long‐term adverse neuro‐psychiatric sequelae. Neural …

This review summarizes current knowledge about the occurrence of hearing and balance
disorders after antimalarial drugs treatment. It also examines the clinical applications of …

Background Tafenoquine was recently approved for Plasmodium vivax radical cure
(KRINTAFEL™) and malaria prevention (ARAKODA™). Methods A review of the non-clinical …

Background Tafenoquine is an 8-aminoquinoline anti-malarial drug recently approved as a
single-dose (300 mg) therapy for Plasmodium vivax relapse prevention, when co …

The directives and evidence concerning drugs for the treatment and prophylaxis of Covid-19
are rapidly evolving. COVID-19 is now pandemic and recent publications in the Asian …